Visgenx is developing therapeutics for Age-Related Macular Degeneration a condition with no approved products and affecting > 196 million worldwide. The therapeutics are based on restoring the age-related dysfunction in the gene underlying the disorder. Our products include a fast to market repurposed drug and a gene therapy solution.
